Versor Investments LP Increases Stock Holdings in Glaukos Corporation $GKOS

Key Points

• Versor Investments LP significantly increased its stake in Glaukos Corporation by 143.9%, holding 13,272 shares valued at approximately $1.31 million as of the end of the recent quarter.
• Glaukos reported earnings of ($0.24) per share, exceeding analysts' expectations and showing a 29.7% year-over-year revenue growth to $124.12 million.
• Overall, institutional investors now own 99.04% of Glaukos' stock, reflecting strong investor interest in the medical instruments supplier's growth potential.

Versor Investments LP boosted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 143.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,272 shares of the medical instruments supplier's stock after acquiring an additional 7,830 shares during the quarter. Versor Investments LP's holdings in Glaukos were worth $1,306,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GKOS. Nuveen LLC purchased a new position in Glaukos during the 1st quarter valued at about $31,474,000. Westfield Capital Management Co. LP boosted its holdings in Glaukos by 34.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock valued at $106,705,000 after acquiring an additional 277,033 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Glaukos by 25.3% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock valued at $123,742,000 after buying an additional 166,677 shares during the period. Voya Investment Management LLC boosted its stake in shares of Glaukos by 266.2% in the 4th quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier's stock valued at $30,093,000 after buying an additional 145,890 shares during the period. Finally, Comerica Bank boosted its stake in shares of Glaukos by 664.5% in the 4th quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier's stock valued at $22,722,000 after buying an additional 131,715 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GKOS has been the subject of several recent research reports. Zacks Research cut Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. William Blair raised Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Truist Financial reissued a "buy" rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Mizuho set a $130.00 target price on Glaukos in a research report on Thursday, July 31st. Finally, Morgan Stanley cut their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Stock Performance

GKOS traded up $4.4170 during trading on Friday, hitting $94.2070. 688,079 shares of the stock were exchanged, compared to its average volume of 1,214,021. The firm has a market capitalization of $5.40 billion, a P/E ratio of -57.10 and a beta of 0.78. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The stock has a fifty day moving average price of $96.26 and a two-hundred day moving average price of $101.46. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm's revenue was up 29.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.